GSK's Lamictal XR Effective in Reducing Seizures in Epilepsy Patients
Posted on: Tuesday, 16 October 2007, 12:00 CDT
GlaxoSmithKline has reported that recently published data show that Lamictal XR extended-release tablets significantly reduced the frequency of partial seizures in inadequately controlled patients with epilepsy.
Results from this international, multi-center, randomized, double-blind, placebo-controlled study have demonstrated that Lamictal XR reduced partial seizures by 46% over the entire 19-week treatment period, compared to 24% with placebo. All patients enrolled in the study were inadequately controlled on one or two anti-epileptic drugs.
The study also showed that 42% of patients treated with Lamictal XR achieved at least a 50% reduction in seizure frequency compared to 24% of patients receiving placebo, a reduction that was reached by some patients as early as day 18 of the study and was sustained over the entire 19-week treatment period.
Dean Naritoku, professor of neurology and pharmacology at Southern Illinois University, said: "Many patients require multiple doses of one or more medications to control their epilepsy, which makes taking their medicines correctly and at the right times even more challenging. These data are important as they show investigational Lamictal XR taken once- daily significantly reduced seizure frequency among previously uncontrolled patients."
Source: Datamonitor
Related Articles
- Joint Replacement Patients with Diabetes Greatly Benefit from Controlled Glucose
- Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
- Vectron International Announces Comprehensive Low Jitter Frequency Control Product Support for Synchronous Ethernet
- SinoFresh Reports Patient Case Study: Allergic Fungal Rhinosinusitis in Adult Male With History of Sinus Conditions
- Atherogenic Lipid Profile and Cardiovascular Risk Factors in HIV- Infected Patients (Ntar Study)
- Genentech Stops Enrolling Patients in Study
- The Immune Response Corporation's NeuroVax Demonstrates Increase in FOXP3 Gene Marker Levels and Treg Cell Functional Activity in MS Patients to Levels Similar to Human Controls
- Study Published in Journal Headache Shows Botox-R- May Reduce the Frequency of Headaches in Patients With a Chronic Form of Migraine
- Benefits of Transdermal Fentanyl in Patients With Rheumatoid Arthritis or With Osteoarthritis of the Knee or Hip: an Open-Label Study to Assess Pain Control
- Stimulation of Insulin Secretion By Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects
 |
 |
User Comments (0)
RSS Feeds